**PLEASE NOTE: SESSION BEGINS AT 3:15 PM ET**
Join the AAGP Journal Club and presenter Christopher van Dyck, MD at 3:15 pm Eastern Time on Friday. January 12, 2024. Dr. van Dyck will not only be discussing the results of this phase 3 clinical trial (CLARITY-AD) but will also discuss some unpublished data from the open-label extension of the study.
ACCME Credit Designation Statement:
Amedco LLC designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM for physicians.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Learning Objectives:
1. Develop an understanding of the evidence behind the FDA approval of Lecanemab for use in early Alzheimer’s disease based on the results of the CLARITY-AD phase 3 clinical trial.
2. Develop an understanding of the difference between disease-modifying therapies (Lecanemab) and symptomatic therapies (Donepezil) for the treatment of Alzheimer’s disease.
How to Get Your Certificate
1. Go to aagp.cmecertificateonline.com
2. Click on the American Association for Geriatric Psychiatry Journal Club – Lecanemab Therapy in Early
Alzheimer’s Disease link.
3. Evaluate the meeting.
4. Print, download, or save your certificate for your records.
5. If you lose your certificate, or need help, go to help.cmecertificateonline.com